Pharmaniaga Berhad Statistics
Total Valuation
KLSE:PHARMA has a market cap or net worth of MYR 970.44 million. The enterprise value is 1.63 billion.
Important Dates
The next estimated earnings date is Friday, November 27, 2026.
| Earnings Date | Nov 27, 2026 |
| Ex-Dividend Date | Dec 23, 2026 |
Share Statistics
KLSE:PHARMA has 1.31 billion shares outstanding. The number of shares has increased by 182.17% in one year.
| Current Share Class | 1.31B |
| Shares Outstanding | 1.31B |
| Shares Change (YoY) | +182.17% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 6.34% |
| Owned by Institutions (%) | 13.96% |
| Float | 341.00M |
Valuation Ratios
The trailing PE ratio is 12.49 and the forward PE ratio is 10.72.
| PE Ratio | 12.49 |
| Forward PE | 10.72 |
| PS Ratio | 0.23 |
| PB Ratio | 2.03 |
| P/TBV Ratio | 2.50 |
| P/FCF Ratio | 50.49 |
| P/OCF Ratio | 8.66 |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
The stock's EV/EBITDA ratio is 10.08, with an EV/FCF ratio of 84.86.
| EV / Earnings | 20.93 |
| EV / Sales | 0.39 |
| EV / EBITDA | 10.08 |
| EV / EBIT | 12.75 |
| EV / FCF | 84.86 |
Financial Position
The company has a current ratio of 1.00, with a Debt / Equity ratio of 1.51.
| Current Ratio | 1.00 |
| Quick Ratio | 0.53 |
| Debt / Equity | 1.51 |
| Debt / EBITDA | 4.71 |
| Debt / FCF | 39.62 |
| Interest Coverage | 2.91 |
Financial Efficiency
Return on equity (ROE) is 16.98% and return on invested capital (ROIC) is 10.37%.
| Return on Equity (ROE) | 16.98% |
| Return on Assets (ROA) | 3.31% |
| Return on Invested Capital (ROIC) | 10.37% |
| Return on Capital Employed (ROCE) | 15.02% |
| Weighted Average Cost of Capital (WACC) | 7.11% |
| Revenue Per Employee | 1.19M |
| Profits Per Employee | 22,252 |
| Employee Count | 3,502 |
| Asset Turnover | 1.73 |
| Inventory Turnover | 5.54 |
Taxes
In the past 12 months, KLSE:PHARMA has paid 7.80 million in taxes.
| Income Tax | 7.80M |
| Effective Tax Rate | 8.80% |
Stock Price Statistics
The stock price has decreased by -38.33% in the last 52 weeks. The beta is 0.79, so KLSE:PHARMA's price volatility has been lower than the market average.
| Beta (5Y) | 0.79 |
| 52-Week Price Change | -38.33% |
| 50-Day Moving Average | 0.90 |
| 200-Day Moving Average | 1.17 |
| Relative Strength Index (RSI) | 33.97 |
| Average Volume (20 Days) | 1,587,130 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KLSE:PHARMA had revenue of MYR 4.17 billion and earned 77.93 million in profits. Earnings per share was 0.06.
| Revenue | 4.17B |
| Gross Profit | 426.36M |
| Operating Income | 127.90M |
| Pretax Income | 88.69M |
| Net Income | 77.93M |
| EBITDA | 151.25M |
| EBIT | 127.90M |
| Earnings Per Share (EPS) | 0.06 |
Full Income Statement Balance Sheet
The company has 125.89 million in cash and 761.56 million in debt, with a net cash position of -635.67 million or -0.48 per share.
| Cash & Cash Equivalents | 125.89M |
| Total Debt | 761.56M |
| Net Cash | -635.67M |
| Net Cash Per Share | -0.48 |
| Equity (Book Value) | 502.79M |
| Book Value Per Share | 0.36 |
| Working Capital | 5.34M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was 112.00 million and capital expenditures -92.78 million, giving a free cash flow of 19.22 million.
| Operating Cash Flow | 112.00M |
| Capital Expenditures | -92.78M |
| Depreciation & Amortization | 23.35M |
| Net Borrowing | -163.90M |
| Free Cash Flow | 19.22M |
| FCF Per Share | 0.01 |
Full Cash Flow Statement Margins
Gross margin is 10.22%, with operating and profit margins of 3.07% and 1.87%.
| Gross Margin | 10.22% |
| Operating Margin | 3.07% |
| Pretax Margin | 2.13% |
| Profit Margin | 1.87% |
| EBITDA Margin | 3.62% |
| EBIT Margin | 3.07% |
| FCF Margin | 0.46% |
Dividends & Yields
This stock pays an annual dividend of 0.02, which amounts to a dividend yield of 2.77%.
| Dividend Per Share | 0.02 |
| Dividend Yield | 2.77% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 2 |
| Payout Ratio | 21.04% |
| FCF Payout Ratio | 139.86% |
| Buyback Yield | -182.17% |
| Shareholder Yield | -179.40% |
| Earnings Yield | 8.01% |
| FCF Yield | 1.98% |
Dividend Details Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside | |
Analyst Forecast
The average price target for KLSE:PHARMA is 1.45, which is 96.35% higher than the current price. The consensus rating is "Buy".
| Price Target | 1.45 |
| Price Target Difference | 96.35% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 5.47% |
| EPS Growth Forecast (3Y) | 8.26% |
Stock Splits
The last stock split was on June 8, 2026. It was a reverse split with a ratio of 0.2.
| Last Split Date | Jun 8, 2026 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
KLSE:PHARMA has an Altman Z-Score of 2.49 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.49 |
| Piotroski F-Score | 6 |